AAAAAA

   
Results: 1-19 |
Results: 19
Development of a dual monoclonal antibody immunoassay for total human kallikrein 2
Authors: Finlay, JA Day, JR Evans, CL Carlson, R Kuus-Reichel, K Millar, LS Mikolajczyk, SD Goodmanson, M Klee, GG Rittenhouse, HG
Citation: Ja. Finlay et al., Development of a dual monoclonal antibody immunoassay for total human kallikrein 2, CLIN CHEM, 47(7), 2001, pp. 1218-1224
A truncated precursor form of prostate-specific antigen is a more specificserum marker of prostate cancer
Authors: Mikolajczyk, SD Marker, KM Millar, LS Kumar, A Saedi, MS Payne, JK Evans, CL Gasior, CL Linton, HJ Carpenter, P Rittenhouse, HG
Citation: Sd. Mikolajczyk et al., A truncated precursor form of prostate-specific antigen is a more specificserum marker of prostate cancer, CANCER RES, 61(18), 2001, pp. 6958-6963
Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia
Authors: Mikolajczyk, SD Millar, LS Marker, KM Wang, TJ Rittenhouse, HG Marks, LS Slawin, KM
Citation: Sd. Mikolajczyk et al., Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia, PROSTATE, 45(3), 2000, pp. 271-276
"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia
Authors: Mikolajczyk, SD Millar, LS Wang, TJ Rittenhouse, HG Wolfert, RL Marks, LS Song, WT Wheeler, TM Slawin, KM
Citation: Sd. Mikolajczyk et al., "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia, UROLOGY, 55(1), 2000, pp. 41-45
Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies
Authors: Wang, TJ Slawin, KM Rittenhouse, HG Millar, LS Mikolajczyk, SD
Citation: Tj. Wang et al., Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies, EUR J BIOCH, 267(13), 2000, pp. 4040-4045
New nomenclature for the human tissue kallikrein gene family
Authors: Diamandis, EP Yousef, GM Clements, J Ashworth, LK Yoshida, S Egelrud, T Nelson, PS Shiosaka, S Little, S Lilja, H Stenman, UH Rittenhouse, HG Wain, H
Citation: Ep. Diamandis et al., New nomenclature for the human tissue kallikrein gene family, CLIN CHEM, 46(11), 2000, pp. 1855-1858
A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue
Authors: Mikolajczyk, SD Millar, LS Wang, TJ Rittenhouse, HG Marks, LS Song, WT Wheeler, TM Slawin, KM
Citation: Sd. Mikolajczyk et al., A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue, CANCER RES, 60(3), 2000, pp. 756-759
The prostate-localized kallikreins: Prostate specific antigen and human kallikrein 2
Authors: Saedi, MS Rittenhouse, HG Finlay, JA Mikolajczyk, SD Partin, AW
Citation: Ms. Saedi et al., The prostate-localized kallikreins: Prostate specific antigen and human kallikrein 2, J CLIN LIG, 22(4), 1999, pp. 371-375
Summary report of the TD-3 workshop: Characterization of 83 antibodies against prostate-specific antigen
Authors: Stenman, UH Paus, E Allard, WJ Andersson, I Andres, C Barnett, TR Becker, C Belenky, A Bellanger, L Pellegrino, CM Bormer, OP Davis, G Dowell, B Grauer, LS Jette, DC Karlsson, B Kreutz, FT van der Kwast, TM Lauren, L Leinimaa, M Leinonen, J Lilja, H Linton, HJ Nap, M Nilsson, O Ng, PC Nustad, K Peter, A Pettersson, K Piironen, T Rapp, J Rittenhouse, HG Rye, PD Seguin, P Slota, J Sokoloff, RL Suresh, MR Very, DL Wang, TJ Wigheden, I Wolfert, RL Yeung, KK Zhang, WM Zhou, Z Hilgers, J
Citation: Uh. Stenman et al., Summary report of the TD-3 workshop: Characterization of 83 antibodies against prostate-specific antigen, TUMOR BIOL, 20, 1999, pp. 1-12
Western blotting analysis of antibodies to prostate-specific antigen: Cross-reactivity with human kallikrein-2
Authors: Wang, TJ Linton, HJ Rittenhouse, HG Wolfert, RL
Citation: Tj. Wang et al., Western blotting analysis of antibodies to prostate-specific antigen: Cross-reactivity with human kallikrein-2, TUMOR BIOL, 20, 1999, pp. 75-78
Western blotting analysis of antibodies to prostate-specific antigen: Specificities for prostate-specific antigen and prostate-specific antigen fragments
Authors: Wang, TJ Linton, HJ Sokoloff, RL Grauer, LS Rittenhouse, HG Wolfert, RL
Citation: Tj. Wang et al., Western blotting analysis of antibodies to prostate-specific antigen: Specificities for prostate-specific antigen and prostate-specific antigen fragments, TUMOR BIOL, 20, 1999, pp. 79-85
Generation of PSA-ACT-specific monoclonal antibodies and their applicationin a sandwich immunoassay
Authors: Wang, TJ Linton, HJ Payne, J Rittenhouse, HG Chan, DW Partin, AW Wolfert, RL Kuus-Reichel, K
Citation: Tj. Wang et al., Generation of PSA-ACT-specific monoclonal antibodies and their applicationin a sandwich immunoassay, HYBRIDOMA, 18(6), 1999, pp. 535-541
Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis
Authors: Partin, AW Catalona, WJ Finlay, JA Darte, C Tindall, DJ Young, CYF Klee, GG Chan, DW Rittenhouse, HG Wolfert, RL Woodrum, DL
Citation: Aw. Partin et al., Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis, UROLOGY, 54(5), 1999, pp. 839-845
Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: An alternative model
Authors: Catalona, WJ Partin, AW Finlay, JA Chan, DW Rittenhouse, HG Wolfert, RL Woodrum, DL
Citation: Wj. Catalona et al., Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: An alternative model, UROLOGY, 54(2), 1999, pp. 220-224
Can complexed PSA be used as a single test for detecting prostate cancer?
Authors: Rittenhouse, HG Chan, DW
Citation: Hg. Rittenhouse et Dw. Chan, Can complexed PSA be used as a single test for detecting prostate cancer?, UROLOGY, 54(1), 1999, pp. 4-5
Polyclonal and monoclonal antibodies to prostate-specific antigen can cross-react with human kallikrein 2 and human kallikrein 1
Authors: Finlay, JA Day, JR Rittenhouse, HG
Citation: Ja. Finlay et al., Polyclonal and monoclonal antibodies to prostate-specific antigen can cross-react with human kallikrein 2 and human kallikrein 1, UROLOGY, 53(4), 1999, pp. 746-751
Serum and semen prostate specific antigen concentrations are different in young spinal cord injured men compared to normal controls
Authors: Lynne, CM Aballa, TC Wang, TJ Rittenhouse, HG Ferrell, SM Brackett, NL
Citation: Cm. Lynne et al., Serum and semen prostate specific antigen concentrations are different in young spinal cord injured men compared to normal controls, J UROL, 162(1), 1999, pp. 89-91
Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2
Authors: Klee, GG Goodmanson, MK Jacobsen, SJ Young, CYF Finlay, JA Rittenhouse, HG Wolfert, RL Tindall, DJ
Citation: Gg. Klee et al., Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2, CLIN CHEM, 45(6), 1999, pp. 800-806
Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue
Authors: Mikolajczyk, SD Millar, LS Marker, KM Rittenhouse, HG Wolfert, RL Marks, LS Charlesworth, MC Tindall, DJ
Citation: Sd. Mikolajczyk et al., Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue, CANCER RES, 59(16), 1999, pp. 3927-3930
Risultati: 1-19 |